Climb Bio, Inc. (CLYM) 10-Year Financial Performance & Capital Metrics

CLYM • • Industrial / General

HealthcareBiotechnologyAutoimmune & Inflammatory DiseasesDermatology & Autoimmune

AboutClimb Bio, Inc., a biotechnology company, focuses on developing therapies for autoimmune-driven inflammatory diseases. It develops budoprutug, an anti-CD19 monoclonal antibody for various autoimmune diseases, including systemic lupus erythematosus and lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wilmington, Delaware.Show more

Revenue $0
EBITDA -$30M +24.6%
Net Income -$74M -110.4%
EPS (Diluted) -1.53 -17.7%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -46.26% -55.6%
ROIC -87.87% -46.1%
Debt/Equity 0.00 -22.6%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Momentum leader: RS Rating 97 (top 3%)
✓Trading at only 0.9x book value

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Low quality earnings: Net income not backed by cash flow
✗Shares diluted 78.5% in last year
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM26.58%

EPS CAGR

10Y-

5Y-

3Y-

TTM64.34%

ROCE

10Y Avg-48.16%

5Y Avg-50.57%

3Y Avg-38.61%

Latest-51.28%

Peer Comparison

Dermatology & Autoimmune

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
AUPHAurinia Pharmaceuticals Inc.	2.01B	15.23	387.53	33.97%	29.28%	21.28%	2.2%	0.21
ARGXargenx SE	49.47B	799.33	62.55	78.6%	23.34%	15.14%		0.01
INVAInnoviva, Inc.	1.48B	19.74	54.83	15.54%	32.78%	12.61%	12.77%	0.65
GLPGGalapagos N.V.	2.25B	34.12	30.46	14.99%	-151.94%	-15.16%		0.00
PTGXProtagonist Therapeutics, Inc.	5.33B	85.23	20.15	6.24%	21.94%	7.11%	3.43%	0.02
ALMSAlumis Inc. Common Stock	2.86B	24.34	-2.34		-11.08%	-63.71%		0.12
ZBIOZenas BioPharma, Inc.	1.21B	22.56	-6	-90%	-12.66%	-96.68%		0.00
ORKAOruka Therapeutics, Inc.	1.55B	32.00	-6.41			-22.44%		0.00

Profit & Loss

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-
Cost of Goods Sold+	0	0	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-
Gross Profit+	0	0	0	0	0	0
Gross Margin %	-	-	-	-	-	-
Gross Profit Growth %	-	-	-	-	-	-
Operating Expenses+	7.45M	20.93M	35.67M	45.13M	40.27M	82.02M
OpEx % of Revenue	-	-	-	-	-	-
Selling, General & Admin	677K	2.42M	12.35M	18.92M	24.86M	16.02M
SG&A % of Revenue	-	-	-	-	-	-
Research & Development	4.02M	9.34M	23.32M	26.21M	15.41M	14.34M
R&D % of Revenue	-	-	-	-	-	-
Other Operating Expenses	2.75M	9.16M	0	0	0	51.66M
Operating Income+	-7.45M	-20.93M	-35.67M	-45.13M	-40.27M	-82.02M
Operating Margin %	-	-	-	-	-	-
Operating Income Growth %	-	-1.81%	-0.7%	-0.27%	0.11%	-1.04%
EBITDA+	-4.7M	-11.77M	-35.67M	-45.13M	-40.27M	-30.36M
EBITDA Margin %	-	-	-	-	-	-
EBITDA Growth %	-	-1.51%	-2.03%	-0.27%	0.11%	0.25%
D&A (Non-Cash Add-back)	0	0	0	0	0	0
EBIT	-4.7M	-11.77M	-35.67M	-45.13M	-40.27M	-30.36M
Net Interest Income+	0	0	0	1.38M	4.62M	8.13M
Interest Income	0	0	0	1.38M	4.62M	8.13M
Interest Expense	0	0	0	0	0	0
Other Income/Expense	899K	257K	-11.81M	-109K	5.16M	8.12M
Pretax Income+	-6.55M	-20.67M	-47.48M	-45.24M	-35.12M	-73.9M
Pretax Margin %	-	-	-	-	-	-
Income Tax+	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%
Net Income+	-6.55M	-20.67M	-47.48M	-45.24M	-35.12M	-73.9M
Net Margin %	-	-	-	-	-	-
Net Income Growth %	-	-2.16%	-1.3%	0.05%	0.22%	-1.1%
Net Income (Continuing)	-6.55M	-20.67M	-47.48M	-45.24M	-35.12M	-73.9M
Discontinued Operations	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0
EPS (Diluted)+	-0.56	-1.97	-4.24	-1.72	-1.30	-1.53
EPS Growth %	-	-2.52%	-1.15%	0.59%	0.24%	-0.18%
EPS (Basic)	-0.56	-1.97	-4.24	-1.72	-1.30	-1.53
Diluted Shares Outstanding	11.66M	11.66M	12.26M	26.31M	26.99M	48.16M
Basic Shares Outstanding	11.66M	11.66M	12.26M	26.31M	26.99M	48.16M
Dividend Payout Ratio	-	-	-	-	-	-

Balance Sheet

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	21.28M	22M	148.25M	134.39M	110.25M	154.87M
Cash & Short-Term Investments	21.22M	20.49M	136.48M	123.57M	106.8M	150.92M
Cash Only	21.22M	20.49M	46.92M	43.59M	93.11M	87.23M
Short-Term Investments	0	0	89.56M	79.98M	13.69M	63.69M
Accounts Receivable	0	0	6.52M	6.49M	2.46M	1.12M
Days Sales Outstanding	-	-	-	-	-	-
Inventory	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-
Other Current Assets	35K	11K	852K	3M	112K	256K
Total Non-Current Assets+	112K	2.63M	24.99M	599K	214K	62.31M
Property, Plant & Equipment	0	0	0	471K	199K	490K
Fixed Asset Turnover	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0
Long-Term Investments	0	0	24.92M	0	0	61.61M
Other Non-Current Assets	112K	2.63M	70K	128K	15K	215K
Total Assets+	21.39M	24.63M	173.24M	134.99M	110.47M	217.19M
Asset Turnover	-	-	-	-	-	-
Asset Growth %	-	0.15%	6.03%	-0.22%	-0.18%	0.97%
Total Current Liabilities+	783K	3.06M	6.03M	6.1M	2.83M	4.93M
Accounts Payable	647K	1.09M	1.4M	750K	66K	705K
Days Payables Outstanding	-	-	-	-	-	-
Short-Term Debt	0	0	0	0	0	0
Deferred Revenue (Current)	0	0	0	0	0	0
Other Current Liabilities	0	551K	0	0	138K	31K
Current Ratio	27.18x	7.18x	24.58x	22.04x	38.92x	31.41x
Quick Ratio	27.18x	7.18x	24.58x	22.04x	38.92x	31.41x
Cash Conversion Cycle	-	-	-	-	-	-
Total Non-Current Liabilities+	0	0	7K	180K	37K	375K
Long-Term Debt	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	180K	15K	375K
Deferred Tax Liabilities	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	7K	0	22K	0
Total Liabilities	783K	3.06M	6.04M	6.28M	2.87M	5.31M
Total Debt+	0	0	0	480K	349K	532K
Net Debt	-21.22M	-20.49M	-46.92M	-43.1M	-92.76M	-86.7M
Debt / Equity	-	-	-	0.00x	0.00x	0.00x
Debt / EBITDA	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-	-
Total Equity+	20.61M	21.57M	167.2M	128.72M	107.6M	211.88M
Equity Growth %	-	0.05%	6.75%	-0.23%	-0.16%	0.97%
Book Value per Share	1.77	1.85	13.64	4.89	3.99	4.40
Total Shareholders' Equity	20.61M	21.57M	167.2M	128.72M	107.6M	211.88M
Common Stock	1K	1K	3K	3K	3K	7K
Retained Earnings	-7.47M	-28.14M	-75.62M	-120.86M	-155.98M	-229.88M
Treasury Stock	0	0	0	0	0	0
Accumulated OCI	0	0	-123K	-358K	-2K	23K
Minority Interest	0	0	0	0	0	0

Cash Flow

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-5.01M	-14.1M	-36.07M	-37.37M	-20.6M	-15.56M
Operating CF Margin %	-	-	-	-	-	-
Operating CF Growth %	-	-1.82%	-1.56%	-0.04%	0.45%	0.24%
Net Income	-6.55M	-20.67M	-47.48M	-45.24M	-35.12M	-73.9M
Depreciation & Amortization	0	0	0	0	0	0
Stock-Based Compensation	0	707K	3.74M	6.99M	12.81M	5.56M
Deferred Taxes	0	0	0	0	0	0
Other Non-Cash Items	1.85M	8.8M	11.84M	674K	-2.05M	51.08M
Working Capital Changes	-309K	-2.94M	-4.17M	210K	3.76M	1.7M
Change in Receivables	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0
Change in Payables	17K	-24K	318K	-653K	-686K	-1.14M
Cash from Investing+	0	8.08M	-114.97M	34.44M	68.98M	-121.09M
Capital Expenditures	0	0	0	0	0	0
CapEx % of Revenue	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-
Investments	-	-	-	-	-	-
Other Investing	0	8.08M	0	0	0	-9.64M
Cash from Financing+	26.24M	4.92M	177.23M	0	841K	130.73M
Debt Issued (Net)	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-
Other Financing	0	0	149K	0	0	10.98M
Net Change in Cash	-	-	-	-	-	-
Free Cash Flow+	-5.01M	-14.1M	-36.07M	-37.37M	-20.6M	-15.56M
FCF Margin %	-	-	-	-	-	-
FCF Growth %	-	-1.82%	-1.56%	-0.04%	0.45%	0.24%
FCF per Share	-0.43	-1.21	-2.94	-1.42	-0.76	-0.32
FCF Conversion (FCF/Net Income)	0.76x	0.68x	0.76x	0.83x	0.59x	0.21x
Interest Paid	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0

Key Ratios

Metric	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-31.76%	-98%	-50.3%	-30.58%	-29.72%	-46.26%
Return on Invested Capital (ROIC)	-	-6678.19%	-44.09%	-32.88%	-60.14%	-87.87%
Debt / Equity	-	-	-	0.00x	0.00x	0.00x
FCF Conversion	0.76x	0.68x	0.76x	0.83x	0.59x	0.21x

Frequently Asked Questions

Growth & Financials

Climb Bio, Inc. (CLYM) grew revenue by 0.0% over the past year. Growth has been modest.

Climb Bio, Inc. (CLYM) reported a net loss of $50.8M for fiscal year 2024.

Dividend & Returns

Climb Bio, Inc. (CLYM) has a return on equity (ROE) of -46.3%. Negative ROE indicates the company is unprofitable.

Climb Bio, Inc. (CLYM) had negative free cash flow of $44.4M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener